- |||||||||| Ibrance (palbociclib) / Pfizer, leuprolide acetate for depot suspension / Generic mfg., fulvestrant / Generic mfg.
Journal: Case report of stage IIIC low-grade serous ovarian cancer in a 13-year-old female treated with novel therapy. (Pubmed Central) - Mar 10, 2025
This case supports the potential role of endocrine-based targeted therapy in managing pediatric LGSOC, offering a viable alternative for patients with limited treatment options. Further research is needed to optimize treatment strategies and improve survival outcomes in this rare population.
- |||||||||| P2 data, Journal: Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study. (Pubmed Central) - Mar 6, 2025
P2
With extended follow-up, palbociclib plus exemestane with ovarian function suppression continued to show a significant benefit in progression-free survival compared with capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer who had been previously treated with tamoxifen; however, no improvement in overall survival was seen. Given the progression-free survival benefit, the upfront use of palbociclib plus endocrine therapy is the preferred option for premenopausal women, although a capecitabine-first strategy might be an alternative treatment strategy for maintaining overall survival in resource-limited settings.
- |||||||||| letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Alopecia as a side effect of fertility treatments in women () - Feb 26, 2025 - Abstract #AAD2025AAD_3544;
Given the psychosocial consequences associated with both infertility and alopecia independently, patients experiencing both may simultaneously carry an unrecognized mental health burden. A better understanding of the prevalence, consequences, and factors influencing ART-associated alopecia is needed to better enhance patient experiences and optimize patient care.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Acute Generalized Exanthematous Pustulosis Linked to Leuprolide (Orange County Convention Center (West Building, Exhibit Hall B4, Poster Center 1)) - Feb 21, 2025 - Abstract #AAD2025AAD_2994;
A better understanding of the prevalence, consequences, and factors influencing ART-associated alopecia is needed to better enhance patient experiences and optimize patient care. The appearance of a previously unreported reaction following leuprolide administration, as observed, indicates a need for further evaluation of the potential diffuse dermatological side effects of leuprolide, possibly by a multi-center chart review.
- |||||||||| Yonsa (abiraterone acetate) / Sun Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial (clinicaltrials.gov) - Feb 21, 2025
P3, N=72, Recruiting,
The appearance of a previously unreported reaction following leuprolide administration, as observed, indicates a need for further evaluation of the potential diffuse dermatological side effects of leuprolide, possibly by a multi-center chart review. Not yet recruiting --> Recruiting
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: Central precocious puberty in a toddler with hypothalamic hamartoma. (Pubmed Central) - Feb 4, 2025
In patients under the age of 4 years showing signs of CPP, HH should be considered as diagnosis. All patients receiving medical treatment should be closely monitored.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., Crysvita (burosumab-twza) / Ultragenyx, Kyowa Kirin
Journal: Combined Treatment With Leuprolide Acetate and Burosumab in X-linked Hypophosphatemia and Precocious Puberty: A Therapeutic Response. (Pubmed Central) - Feb 3, 2025
Thus, CPP can be treated in patients with XLH, who may have compromised height outcomes, using synthetic gonadotropin-releasing hormone analogs. In the described XLH patient with CPP, the combined use of gonadotropin-releasing hormone analogs and burosumab was a safe strategy to stabilize pubertal progression and bone age, minimize anthropometric loss, and avoid exacerbating bone deformities.
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, Nubeqa (darolutamide) / Bayer, Orion Corp, Erleada (apalutamide) / J&J
MODULE 3: Evolving Role of Treatment Intensification with Androgen Receptor (AR) Pathway Inhibitors for Nonmetastatic and Metastatic Prostate Cancer (San Francisco Marriott Marquis, 780 Mission Street, San Francisco, California, Golden Gate Ballroom, Salon A (B2 Level); In-Person) - Jan 20, 2025 - Abstract #ASCOGU2025ASCO_GU_1029;
This activity is supported by an educational grant from Astellas and Pfizer Inc. Rationale for the evaluation of treatment intensification with AR pathway inhibitors combined with androgen deprivation therapy (ADT) for patients with nonmetastatic hormone-sensitive prostate cancer (nmHSPC) Major efficacy and safety findings from the Phase III EMBARK trial evaluating enzalutamide and leuprolide versus enzalutamide or leuprolide alone for patients with nmHSPC and high-risk biochemical recurrence after definitive therapy FDA approval and optimal application in clinical practice of enzalutamide with and without ADT Clinical, biological and practical factors guiding the selection of therapy for metastatic hormone-sensitive prostate cancer (mHSPC) Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with mHSPC; appropriate integration of these therapies into practice Published outcomes from the Phase III ARANOTE study evaluating the addition of darolutamide to ADT for patients with mHSPC; clinical implications Key efficacy and safety data from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC; selection of optimal candidates for triplet therapy
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: The role of body composition and appetite-regulating hormones in idiopathic central precocious puberty and their changes during GnRH analog therapy. (Pubmed Central) - Jan 13, 2025
Rationale for the evaluation of treatment intensification with AR pathway inhibitors combined with androgen deprivation therapy (ADT) for patients with nonmetastatic hormone-sensitive prostate cancer (nmHSPC) Major efficacy and safety findings from the Phase III EMBARK trial evaluating enzalutamide and leuprolide versus enzalutamide or leuprolide alone for patients with nmHSPC and high-risk biochemical recurrence after definitive therapy FDA approval and optimal application in clinical practice of enzalutamide with and without ADT Clinical, biological and practical factors guiding the selection of therapy for metastatic hormone-sensitive prostate cancer (mHSPC) Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with mHSPC; appropriate integration of these therapies into practice Published outcomes from the Phase III ARANOTE study evaluating the addition of darolutamide to ADT for patients with mHSPC; clinical implications Key efficacy and safety data from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC; selection of optimal candidates for triplet therapy While appetite-regulating hormones do not seem to directly contribute to precocious puberty pathogenesis, puberty blockade was shown to lead to altered levels of these hormones along with changes in body composition.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg.
Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results. (Level 1, West Hall; Poster Bd #: K17) - Jan 7, 2025 - Abstract #ASCOGU2025ASCO_GU_967;
P1/2
Our phase I findings support the short-term safety and tolerability of the combination of SBRT to the prostate and nodes, ADT, AAP, and niraparib at an MTD of 200 mg in men with high-risk or node positive PCa. Our trial completed phase II enrollment in May 2024, and longer-term safety, efficacy, and genomic correlations will be presented in the future.
- |||||||||| Herceptin (trastuzumab) / Roche
Retrospective data, Journal: Combined systemic treatments in two patients with ductal salivary carcinoma. (Pubmed Central) - Dec 12, 2024
Although they responded favorably to the combined therapy, the addition of antiandrogen, anti-HER2, and chemotherapy did not appear to enhance efficacy. The use of combined target therapy seems to be effective in selected patients, but this indication requires further investigation through prospective studies.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Trial completion date, Trial primary completion date: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Dec 6, 2024
P2, N=23, Active, not recruiting,
No abstract available Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., fludrocortisone / Generic mfg., hydrocortisone / Generic mfg.
Journal: A rare case of central precocious puberty in a male infant with adrenal hypoplasia congenita. (Pubmed Central) - Dec 2, 2024
Our observations may contribute to the understanding of factors influencing normal and abnormal puberty in infants. Increased awareness of the possibility of CPP in AHC will aid clinicians in the earlier clinical and laboratory detection of this complication.
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, Erleada (apalutamide) / J&J
Trial completion: Micro RNAs to Predict Response to Androgen Deprivation Therapy (clinicaltrials.gov) - Nov 24, 2024
P=N/A, N=42, Completed,
Processing parameter modification contributes to small microspheres with high loading capacity and controlled initial burst phase. Active, not recruiting --> Completed
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Review, Journal: Medical Management of Reproduction in Birds. (Pubmed Central) - Nov 20, 2024
Surgical intervention in female birds by means of salpingohysterectomy (oviduct removal) presents significant surgical and anesthetic risks due to the unique and highly vascular reproductive anatomy. This article presents current literature on the medical management of reproduction in birds.
- |||||||||| tranexamic acid oral / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Laparoscopic Hybrid Myomectomy: An Alternative to Large Vertical Midline Laparotomy (Exhibit Hall; Virtual) - Nov 17, 2024 - Abstract #AAGL2024AAGL_985;
Hybrid laparoscopic myomectomy with small laparotomy can be utilized in cases of extreme fibroid burden as an alternative to large vertical midline incision. This approach may offer less invasive surgery while maximizing recovery, fibroid removal, and cosmesis.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Extreme Hysteroscopic Myomectomy for Delivering Fibroids (Room: 276) - Nov 17, 2024 - Abstract #AAGL2024AAGL_329;
Preoperative imaging and examination are key to planning and can change rapidly. Pregnancy and uterine artery embolization can incite fibroid degeneration with delivery of submucosal fibroids, and rarely subsequent infection.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: Premature ovarian insufficiency in pediatric cancer patients: a 10 year Rady Children's hospital experience. (Pubmed Central) - Nov 13, 2024
This retrospective review demonstrates that POI can occur in pediatric cancer survivors, emphasizing the importance of educating patients on potential long-term effects of cancer treatment and importance of routine surveillance. This study confirmed that recovery of ovarian function is possible, especially when diagnosed at a younger age, making continued monitoring essential.
- |||||||||| Yonsa (abiraterone acetate) / Sun Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial (clinicaltrials.gov) - Oct 21, 2024
P3, N=72, Not yet recruiting,
- |||||||||| carboplatin / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., tamoxifen / Generic mfg.
Journal, Metastases: Successful Neoadjuvant Chemotherapy and Surgical Removal of a Nonmetastatic Testicular Round Cell Tumor in a Solomon Island Eclectus Parrot (Eclectus roratus solomonensis). (Pubmed Central) - Oct 15, 2024
Tamoxifen and the gonadotropin-releasing hormone agonists leuprolide and deslorelin were administered as neoadjunctive endocrine therapies...Four doses of carboplatin 15 mg/kg IV were administered as neoadjunctive chemotherapy, and testicular size decreased by approximately 95%...Seven months following surgery, a contrast CT scan did not show any evidence of recurrence of or metastasis from the original mass. This is the first report of successful treatment of a testicular tumor in a psittacine with neoadjuvant chemotherapy and orchidectomy.
- |||||||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Journal, Metastases: Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report. (Pubmed Central) - Oct 14, 2024
Relugolix plus enzalutamide produced a sustained reduction in PSA and the combination was well tolerated. Further research including real world data should assess relugolix in doublet and triplet combinations for prostate cancer.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Biomarker, Enrollment change: Menopausal Sleep Fragmentation and Body Fat Gain (clinicaltrials.gov) - Oct 7, 2024
P4, N=41, Completed,
Further research including real world data should assess relugolix in doublet and triplet combinations for prostate cancer. N=125 --> 41
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Her2-positive breast cancer in a young patient with Li-Fraumeni syndrome: A comprehensive case study. (Pubmed Central) - Sep 24, 2024
Managing Li-Fraumeni syndrome (LFS) and its associated cancers, particularly in young patients, necessitates a comprehensive and multidisciplinary approach. Early genetic testing for TP53 mutations is crucial in identifying LFS, enabling personalized treatment plans and proactive surveillance strategies.
- |||||||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Nubeqa (darolutamide) / Bayer, Orion Corp, Soliris (eculizumab) / AstraZeneca
New Therapies and New Challenges: Radioligand Therapy-Related Thrombotic Microangiopathy in the Kidneys (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3704;
Therapy was changed to enzalutamide and darolutamide for new bone lesions...Losartan was started for hypertension and proteinuria...Our case is a distinctive illustration of kidney side effects of RLT. With the expanding use of RLT, it is vital to educate nephrologists to recognize the kidney effects and develop strategies to prevent rapid decline in kidney function.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: PROSTSIZE: Prostatic Size Reduction Following of Leuprorelin Acetate (clinicaltrials.gov) - Sep 19, 2024
P=N/A, N=40, Recruiting,
With the expanding use of RLT, it is vital to educate nephrologists to recognize the kidney effects and develop strategies to prevent rapid decline in kidney function. Trial primary completion date: Jul 2024 --> Dec 2024
- |||||||||| Ibrance (palbociclib) / Pfizer
Journal, Metastases: From Breast to Orbit: A Case Report of Metastatic Breast Cancer With Orbital Involvement. (Pubmed Central) - Sep 17, 2024
Systemic treatment was started with hormonal therapy fulvestrant and luteinizing hormone-releasing hormone (LHRH), leuprolide, accompanied by palbociclib. As the incidence of ocular metastasis from breast cancer increases, oncologists need to be vigilant about symptoms and use appropriate diagnostic techniques.
|
